Provided by Tiger Fintech (Singapore) Pte. Ltd.

Amneal Pharmaceuticals, Inc.

7.74
+0.08001.04%
Volume:3.16M
Turnover:24.38M
Market Cap:2.43B
PE:-20.46
High:7.85
Open:7.63
Low:7.48
Close:7.66
Loading ...

Amneal Pharmaceuticals Inc expected to post earnings of 15 cents a share - Earnings Preview

Reuters
·
30 Apr

3 Profitable Stocks Skating on Thin Ice

StockStory
·
29 Apr

Amneal Donates $1.5 Million to Support Patients During Parkinson’s Awareness Month

Business Wire
·
11 Apr

Amneal Pharmaceuticals Down Nearly 9%, on Pace for Largest Percent Decrease Since October 2023 -- Data Talk

Dow Jones
·
10 Apr

Press Release: Amneal to Report First Quarter 2025 Results on May 2, 2025

Dow Jones
·
09 Apr

BRIEF-Amneal Announces New Data From Phase 3 Study

Reuters
·
07 Apr

Amneal Pharmaceuticals Inc - Crexont Improves Pdss-2 Scores by -2.35

THOMSON REUTERS
·
07 Apr

Amneal Announces New Data From Phase 3 Study Showing Significant Improvements in Sleep Quality With Crexont® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease

THOMSON REUTERS
·
07 Apr

Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson’s Disease

Business Wire
·
07 Apr

Amneal Pharmaceuticals' Crexont Added to Three Insurance Coverage Accounts

MT Newswires Live
·
03 Apr

Amneal Pharmaceuticals announces expanded coverage for Crexont

TIPRANKS
·
03 Apr

BRIEF-Amneal Announces Expanded Coverage For Crexont® To Enhance Access For Parkinson’S Disease Patients In The U.S.

Reuters
·
03 Apr

Amneal Announces Expanded Coverage for Crexont® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.

THOMSON REUTERS
·
03 Apr

Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson’s Disease Patients in the U.S.

Business Wire
·
03 Apr

BUZZ-India's Shilpa Medicare gains on launch of new version of cancer drug

Reuters
·
03 Apr

Amneal Pharmaceuticals announces U.S. launch of Boruzu

TIPRANKS
·
01 Apr

Amneal Launches Boruzu™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma

THOMSON REUTERS
·
01 Apr

Amneal Launches BORUZU™, First Ready-to-Use Bortezomib Injection for Multiple Myeloma and Mantle Cell Lymphoma

Business Wire
·
01 Apr

Amneal Pharmaceuticals (AMRX) Stock Soars 45% on Success of New Parkinson’s Treatment

TIPRANKS
·
18 Mar

Amneal to Participate at Upcoming Investor Conference

Business Wire
·
11 Mar